Search results
Showing 1 to 14 of 14 results for ixazomib
Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
In development Reference number: GID-TA11203 Expected publication date: 30 April 2026
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
In development Reference number: GID-TA10979 Expected publication date: TBC
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.
We are listening to your views on this Technology appraisal guidance. Comments close 16 April 2026.
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
Discontinued Reference number: GID-TA10254
Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone for previously treated multiple myeloma in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 870.
Discontinued Reference number: GID-TA10843
In development Reference number: GID-TA10589 Expected publication date: TBC